Publications by authors named "Filippo Merloni"

Claim this Profile
P
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.
Samanta Sarti, Alessandro Adriano Viansone, Olga Serra, Chiara Casadei, Lorenzo Cecconetto, Filippo Merloni

Cancers (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants.
Michela Palleschi, Alessandra Virga, Emanuela Scarpi, Eugenio Fonzi, Antonino Musolino, Filippo Merloni

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives.
Filippo Merloni, Michela Palleschi, Caterina Gianni, Marianna Sirico, Riccardo Serra

Clin Exp Metastasis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel , , , , , and NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors.
Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni

Biomedicines· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives" [Crit. Rev. Oncol./Hematol. 181 (2023) 103900].
Marianna Sirico, Alessandra Virga, Benedetta Conte, Milena Urbini, Paola Ulivi, Filippo Merloni

Crit Rev Oncol Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.
Filippo Merloni, Michela Palleschi, Chiara Casadei, Antonino Romeo, Annalisa Curcio

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
Marianna Sirico, Alessandra Virga, Benedetta Conte, Milena Urbini, Paola Ulivi, Filippo Merloni

Crit Rev Oncol Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy.
Marianna Sirico, Alberto D'Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Locoregional treatment of stage IV breast cancer in the era of modern oncology.
Filippo Merloni, Michela Palleschi, Caterina Gianni, Chiara Casadei, Annalisa Curcio

Front Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
Caterina Gianni, Michela Palleschi, Filippo Merloni, Sara Bleve, Chiara Casadei

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer.
Caterina Gianni, Michela Palleschi, Filippo Merloni, Giandomenico Di Menna, Marianna Sirico

Int J Mol Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment.
Caterina Gianni, Michela Palleschi, Giuseppe Schepisi, Chiara Casadei, Sara Bleve, Filippo Merloni

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer patient perspective in the arena of COVID-19 pandemic.
Zelmira Ballatore, Filippo Merloni, Nicoletta Ranallo, Lucia Bastianelli, Francesca Vitarelli

Psychooncology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience.
Mirco Pistelli, Valentina Natalucci, Laura Scortichini, Veronica Agostinelli, Edoardo Lenci, Filippo Merloni

Cancers (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience.
Mirco Pistelli, Filippo Merloni, Sonia Crocetti, Laura Scortichini, Laura Tassone

J Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.
Luca Cantini, Federica Pecci, Filippo Merloni, Andrea Lanese, Edoardo Lenci

Explor Target Antitumor Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis.
Luca Cantini, Filippo Merloni, Silvia Rinaldi, Edoardo Lenci, Giulia Marcantognini

Crit Rev Oncol Hematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic.
Zelmira Ballatore, Lucia Bastianelli, Filippo Merloni, Nicoletta Ranallo, Luca Cantini

JCO Glob Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Filippo Merloni

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Luca Cantini, Mirco Pistelli, Filippo Merloni, Andrea Fontana, Ilaria Bertolini

Clin Breast Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.
Filippo Merloni, Nicoletta Ranallo, Laura Scortichini, Riccardo Giampieri, Rossana Berardi

Cancer Drug Resist· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-responders to anti-HER2 therapies: A case report and review of the literature.
Luca Cantini, Mirco Pistelli, Agnese Savini, Lucia Bastianelli, Arianna Della Mora, Filippo Merloni

Mol Clin Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis